Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-09-04
2008-07-29
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C424S439000
Reexamination Certificate
active
07405238
ABSTRACT:
Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, β-casomorphins, α-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4′-aryl-4′-hydroxypipendino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.
REFERENCES:
patent: 3492131 (1970-01-01), Schlatter et al.
patent: 3689486 (1972-09-01), Clauss et al.
patent: 3714159 (1973-01-01), Janssen et al.
patent: 3914434 (1975-10-01), Bohni
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4470980 (1984-09-01), Higuchi et al.
patent: 4871546 (1989-10-01), Feltz et al.
patent: 5043328 (1991-08-01), Weithmann
patent: 5213794 (1993-05-01), Fritsch et al.
patent: 5328697 (1994-07-01), Raman et al.
patent: 5340590 (1994-08-01), Wong et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5516524 (1996-05-01), Kais et al.
patent: 5686094 (1997-11-01), Acharya
patent: 5938654 (1999-08-01), Wong et al.
patent: 3217071 (1983-11-01), None
patent: 0571217 (1993-11-01), None
patent: 0715846 (1996-06-01), None
patent: 1029892 (2000-08-01), None
patent: 1330829 (1973-09-01), None
patent: WO 97/47285 (1997-12-01), None
patent: WO 99/25321 (1999-05-01), None
MacKenzie et al, 113:CA96305, 1990.
Sund et al., Glucose and Cation Transport in Rat Jejunum. Ileum and Colon in vivo; Acta. Pharmacol. et Toxicol. 1978, 42:253-258.
Fox et al., Surfactants Selectively Ablate Enteric Neurons of the Rat Jejunum, J. Pharmacol. & Exptl. Therapeutics 1983, 227: 538-544.
MacKenzie et al., Three-Generation Reproduction Study with Dioctyl Sodium Sulfosuccinate in Rats; Fundamental and Applied Toxicology 1990, 15:53-62.
Efentakis et al., “The influence of surfactants on drug release from a hydrophobic matrix,” International Journal of Pharmaceutics, 1991, pp. 153-158, vol. 70(1-2).
Stephens et al., “Osmolyte and tryptophan receptors controlling gastric emptying in the dog,” American Journal of Physiology, 1976, pp. 848-853, vol. 231.
Groning et al., Drug Development and Industrial Pharmacy, 10:4:527-539 (1984).
Groning et al., International Journal of Pharmaceutics 56:11-16 (1989).
Binder, Colonic Secretion; chapter 39 of Physiology of the Gastrointestinal Tract, vol. 2 (Johnson et al., ed.) (Raven Press, New York 1981), pp. 1003-1019.
Moes, Gastroretentive Dosage Forms, Critical Reviews in Therapeutic Drug Carrier Systems, 1993, vol. 10 pp. 143-195.
Berner Bret
Markey Micheline
Shell John W.
Depomed Inc.
Hui San-ming
LandOfFree
Pharmacological inducement of the fed mode for enhanced drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmacological inducement of the fed mode for enhanced drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacological inducement of the fed mode for enhanced drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966086